Home Cart 0 Sign in  
X

[ CAS No. 3182-95-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 3182-95-4
Chemical Structure| 3182-95-4
Chemical Structure| 3182-95-4
Structure of 3182-95-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 3182-95-4 ]

Related Doc. of [ 3182-95-4 ]

Alternatived Products of [ 3182-95-4 ]

Product Details of [ 3182-95-4 ]

CAS No. :3182-95-4 MDL No. :MFCD00004732
Formula : C9H13NO Boiling Point : -
Linear Structure Formula :- InChI Key :STVVMTBJNDTZBF-VIFPVBQESA-N
M.W : 151.21 Pubchem ID :447213
Synonyms :
(S)-3-Phenyl-2-amino-1-propanol;(S)-Phenylalaninol
Chemical Name :(S)-2-Amino-3-phenylpropan-1-ol

Calculated chemistry of [ 3182-95-4 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.33
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 2.0
Molar Refractivity : 44.89
TPSA : 46.25 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.72 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.56
Log Po/w (XLOGP3) : 0.71
Log Po/w (WLOGP) : 0.55
Log Po/w (MLOGP) : 1.26
Log Po/w (SILICOS-IT) : 1.32
Consensus Log Po/w : 1.08

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.43
Solubility : 5.61 mg/ml ; 0.0371 mol/l
Class : Very soluble
Log S (Ali) : -1.26
Solubility : 8.32 mg/ml ; 0.0551 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.3
Solubility : 0.753 mg/ml ; 0.00498 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.32

Safety of [ 3182-95-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 UN#:N/A
Hazard Statements:H315-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 3182-95-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 3182-95-4 ]
  • Downstream synthetic route of [ 3182-95-4 ]

[ 3182-95-4 ] Synthesis Path-Upstream   1~16

  • 1
  • [ 3182-95-4 ]
  • [ 59830-60-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 24, p. 5449 - 5460
[2] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 6, p. 705 - 710
[3] Heterocycles, 1987, vol. 26, # 11, p. 2805 - 2809
[4] Journal of the American Chemical Society, 1994, vol. 116, # 4, p. 1316 - 1323
[5] Journal of Organic Chemistry, 1992, vol. 57, # 1, p. 28 - 32
[6] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1988, p. 535 - 540
[7] European Journal of Organic Chemistry, 2018, vol. 2018, # 27, p. 3844 - 3852
  • 2
  • [ 79-37-8 ]
  • [ 3182-95-4 ]
  • [ 59830-60-3 ]
Reference: [1] Patent: US5362912, 1994, A,
  • 3
  • [ 3182-95-4 ]
  • [ 28920-43-6 ]
  • [ 129397-83-7 ]
YieldReaction ConditionsOperation in experiment
89% at 20℃; for 0.0333333 h; Sonication; Irradiation; Green chemistry General procedure: Amine (1 mmol) and Fmoc-Cl (1.1 mmol) were placed in a glass tube under neat conditions and were sonicated for a suitable time (as indicated in Tables 1, 2 and 3). All reactions were performed in a water bath at room temperature. After completion of the reaction (as indicated by TLC), 5 cm3 of diethyl ether was added to the mixture. The N-Fmoc derivatives were crystallized and were obtained in good to excellent yields. Purification of the product was accomplished by recrystallization from diethyl ether.
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 1, p. 404 - 414
[2] Journal of the Brazilian Chemical Society, 2016, vol. 27, # 3, p. 546 - 550
[3] Journal of Organic Chemistry, 1995, vol. 60, # 2, p. 405 - 410
[4] Journal of the American Chemical Society, 2006, vol. 128, # 12, p. 4023 - 4034
  • 4
  • [ 3182-95-4 ]
  • [ 82911-69-1 ]
  • [ 129397-83-7 ]
Reference: [1] Tetrahedron, 1995, vol. 51, # 45, p. 12337 - 12350
[2] Tetrahedron, 1998, vol. 54, # 34, p. 10125 - 10152
[3] Tetrahedron Letters, 1995, vol. 36, # 1, p. 167 - 168
  • 5
  • [ 7321-55-3 ]
  • [ 3182-95-4 ]
  • [ 112245-13-3 ]
  • [ 131833-93-7 ]
  • [ 176706-98-2 ]
Reference: [1] Tetrahedron Asymmetry, 2006, vol. 17, # 15, p. 2270 - 2275
  • 6
  • [ 3182-95-4 ]
  • [ 141403-49-8 ]
Reference: [1] Tetrahedron, 2007, vol. 63, # 39, p. 9758 - 9763
[2] Angewandte Chemie - International Edition, 2000, vol. 39, # 15, p. 2752 - 2754
[3] Journal of Medicinal Chemistry, 1992, vol. 35, # 7, p. 1259 - 1266
[4] Organometallics, 2014, vol. 33, # 22, p. 6452 - 6465
  • 7
  • [ 3182-95-4 ]
  • [ 131288-67-0 ]
Reference: [1] Synthetic Communications, 2000, vol. 30, # 22, p. 4173 - 4176
  • 8
  • [ 2577-90-4 ]
  • [ 3182-95-4 ]
  • [ 131288-67-0 ]
Reference: [1] Advanced Synthesis and Catalysis, 2001, vol. 343, # 8, p. 802 - 808
  • 9
  • [ 3182-95-4 ]
  • [ 108-24-7 ]
  • [ 52485-51-5 ]
YieldReaction ConditionsOperation in experiment
90% at 20℃; for 0.166667 h; Green chemistry In a 50mL round-bottomed flask, a mixtureof amine or amino alcohol (1 mmol) and aceticanhydride (1.2 mmol) was stirred at roomtemperature for the appropriate time. Aftercompletion of the reaction, as monitored by TLC,the reaction mixture was dissolved in ether (5 mL)and was allowed to stand at room temperature for1 hour. During this time, crystal of product formed,which were collected by filtration.In the case of solid substrates(sulfonamides), the same protocol was used.However, the use of water was required for thesolubility of the mixture. The N-acylatedsulfonamides were collected by crystallization fromdiethyl ether.
78% at -20℃; for 2 h; To a solution of l-phenylalaninol (1 g, 6.6 mmol) in pyridine (20 mL) at -20 °C, acetic anhydride (0.7 mL, 7.26 mmol) was added dropwise, and the solution was stirred at -20 °C for 2 h after which TLC (EtOAc/CH2Cl2/MeOH 6:2:2) (stained with ninhydrin) showed no starting material. The reaction was quenched with methanol (3 mL) then evaporated in vacuo. The residue was dissolved in EtOAc (15 mL), washed with water (2 x 15 mL), brine (2 x 15 mL), dried over anhydrous MgSO4 and filtered. The filtrate was evaporated to dryness to afford 11 as white needles which was recrystallized from EtOAc, (1.1 g, 78percent); mp 98-99 °C; 1H NMR (270 MHz, CDCl3): δ 7.25-7.21 (m, 5H, Ar), δ 5.7 (br s, 1H, NH), δ 4.15-4.12 (m, 1H, CH-NH), δ 3.66-3.58 (m, 2H, CH2-OH), δ 2.87-2.84 (d, 2H, CH2-Ph), δ 2.64-2.62 (t, 1H, OH), δ 2.03 (s, 3H, Ac); HRMS (ESI+): (Mwt. 193); m/z found: 194.1168 [M+H]+, C11H16NO2 requires 194.1181 and 216.0987 [M+Na]+, C11H15NO2Na requires 216.1000.
75% for 16 h; To a stirred solution of L-phenylalaninol (228 mg, 1.51 mmol) in THF (5 mL) was added acetic anhydride (0.15 mL, 1.59 mmol) and the mixture stirred for 16 h. The reaction mixture was diluted with EtOAc (10 mL) and washed with 1 N HCL (15 mL), saturated aqueous sodium bicarbonate (15 mL) and brine (15 mL). The organic phase was dried (MgSO4), filtered and concentrated in vacuo. Purification of the residue by column chromatography on silica gel afforded the N-acetylated alcohol (220 mg, 75percent) as a white solid. 1H NMR (CDCl3) δ 1.95 (s, 3H), 2.87 (d, 2H, J=6.0 Hz), 3.17 (br s, 1H), 3.56-3.68 (m, 2H), 4.13-4.21 (m, 1H), 5.97 (br d, 1H, J=6.0 Hz), 7.20-7.34 (m, 5H). The alcohol was then oxidized according to the general Dess-Martin procedure and the crude aldehyde used without further purification.
Reference: [1] Chinese Chemical Letters, 2010, vol. 21, # 2, p. 155 - 158
[2] Oriental Journal of Chemistry, 2015, vol. 31, # 2, p. 913 - 919
[3] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 10, p. 2742 - 2755
[4] Patent: US6750348, 2004, B1, . Location in patent: Page column 47
[5] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 6, p. 2216 - 2220
  • 10
  • [ 3182-95-4 ]
  • [ 75-36-5 ]
  • [ 52485-51-5 ]
Reference: [1] Heterocycles, 1995, vol. 41, # 5, p. 947 - 958
  • 11
  • [ 108-22-5 ]
  • [ 3182-95-4 ]
  • [ 52485-51-5 ]
Reference: [1] Green Chemistry, 2012, vol. 14, # 8, p. 2251 - 2255
  • 12
  • [ 3182-95-4 ]
  • [ 165727-45-7 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 2010, vol. 53, # 3, p. 148 - 152
  • 13
  • [ 75-15-0 ]
  • [ 3182-95-4 ]
  • [ 171877-39-7 ]
Reference: [1] Tetrahedron, 2008, vol. 64, # 24, p. 5637 - 5644
[2] European Journal of Organic Chemistry, 2009, # 33, p. 5841 - 5846
[3] Organic Letters, 2008, vol. 10, # 13, p. 2821 - 2824
[4] Journal of Organic Chemistry, 1995, vol. 60, # 20, p. 6604 - 6607
[5] Journal of the Chemical Society - Perkin Transactions 1, 1997, # 14, p. 2139 - 2145
[6] Organic Letters, 2000, vol. 2, # 6, p. 775 - 777
[7] Journal of Organic Chemistry, 2001, vol. 66, # 3, p. 894 - 902
[8] Journal of Organic Chemistry, 2001, vol. 66, # 3, p. 894 - 902
[9] Patent: WO2008/23336, 2008, A2, . Location in patent: Page/Page column 55
[10] Journal of Medicinal Chemistry, 2013, vol. 56, # 15, p. 6156 - 6174
[11] Organic Syntheses, 2011, vol. 88, p. 364 - 376
[12] Phosphorus, Sulfur and Silicon and the Related Elements, 2015, vol. 190, # 1, p. 112 - 122
  • 14
  • [ 3182-95-4 ]
  • [ 171877-39-7 ]
Reference: [1] Journal of the Chemical Society - Perkin Transactions 1, 1997, # 14, p. 2139 - 2145
[2] Journal of Organic Chemistry, 1995, vol. 60, # 20, p. 6604 - 6607
[3] Organic Letters, 2012, vol. 14, # 21, p. 5396 - 5399
[4] Patent: WO2013/148324, 2013, A1,
  • 15
  • [ 75-15-0 ]
  • [ 3182-95-4 ]
  • [ 131744-19-9 ]
  • [ 171877-39-7 ]
Reference: [1] Journal of the Chemical Society - Perkin Transactions 1, 1997, # 14, p. 2139 - 2145
  • 16
  • [ 3182-95-4 ]
  • [ 1088965-37-0 ]
Reference: [1] Organic Process Research and Development, 2010, vol. 14, # 5, p. 1254 - 1263
[2] Organic Process Research and Development, 2010, vol. 14, # 5, p. 1254 - 1263
[3] Organic Process Research and Development, 2010, vol. 14, # 5, p. 1254 - 1263
[4] Organic Process Research and Development, 2010, vol. 14, # 5, p. 1254 - 1263
[5] Organic Process Research and Development, 2010, vol. 14, # 5, p. 1254 - 1263
[6] Organic Process Research and Development, 2010, vol. 14, # 5, p. 1254 - 1263
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 3182-95-4 ]

Ritonavir Related Intermediates

Chemical Structure| 144163-97-3

[ 144163-97-3 ]

4-Nitrophenyl (thiazol-5-ylmethyl) carbonate

Chemical Structure| 154212-60-9

[ 154212-60-9 ]

2-Isopropyl-4-(methylaminomethyl)thiazole

Chemical Structure| 6306-52-1

[ 6306-52-1 ]

H-Val-OMe.HCl

Chemical Structure| 38585-74-9

[ 38585-74-9 ]

Thiazol-5-ylmethanol

Chemical Structure| 563-83-7

[ 563-83-7 ]

Isobutyramide